Data gathered: January 10
Alternative Data for Coherus BioSciences
Alternative Data | Value | 3m Change | Trend | Benchmark | |
---|---|---|---|---|---|
Sentiment | 98 | Sign up | Sign up | Sign up | |
Webpage traffic | 59,000 | Sign up | Sign up | Sign up | |
Google Trends | 9 | Sign up | Sign up | Sign up | |
4chan Mentions | N/A | Sign up | Sign up | Sign up | |
Reddit Mentions | N/A | Sign up | Sign up | Sign up | |
Stocktwits Mentions | 40 | Sign up | Sign up | Sign up | |
Stocktwits Subscribers | 4,976 | Sign up | Sign up | Sign up | |
Twitter Mentions | 15 | Sign up | Sign up | Sign up | |
News Mentions | N/A | Sign up | Sign up | Sign up | |
Customer reviews | N/A | Sign up | Sign up | Sign up |
About Coherus BioSciences
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
Price | $1.47 |
Target Price | Sign up |
Volume | 872,130 |
Market Cap | $174M |
Year Range | $0.67 - $2.27 |
Dividend Yield | 0% |
Analyst Rating | 100% buy |
Industry | Biotechnology |
In the news
Coherus BioSciences (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving Average – Here’s WhyJanuary 8 - ETF Daily News |
|
Coherus BioSciences (NASDAQ:CHRS) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What HappenedDecember 31 - ETF Daily News |
|
Analyzing Scinai Immunotherapeutics (NASDAQ:SCNI) & Coherus BioSciences (NASDAQ:CHRS)December 22 - ETF Daily News |
|
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing DevelopmentDecember 16 - SeekingAlpha |
|
Jacobs Levy Equity Management Inc. Has $262,000 Stock Holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS)December 11 - ETF Daily News |
|
Robert W. Baird Forecasts Strong Price Appreciation for Coherus BioSciences (NASDAQ:CHRS) StockDecember 6 - ETF Daily News |
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
---|---|---|---|---|---|---|
Q3 '24 | 71M | 57M | 14M | -11M | -4.8M | -0.010 |
Q2 '24 | 52M | 64M | -12M | -13M | -19M | -0.140 |
Q1 '24 | 66M | 93M | -27M | 103M | -41M | -0.320 |
Q4 '23 | 81M | 135M | -54M | -80M | -68M | -0.620 |
Q3 '23 | 64M | 81M | -17M | -40M | -29M | -0.410 |
Insider Transactions View All
Lanfear Dennis M filed to sell 731,693 shares at $2. November 24 '23 |
Similar companies
Read more about Coherus BioSciences (CHRS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Coherus BioSciences?
The Market Cap of Coherus BioSciences is $174M.
What is the current stock price of Coherus BioSciences?
Currently, the price of one share of Coherus BioSciences stock is $1.47.
How can I analyze the CHRS stock price chart for investment decisions?
The CHRS stock price chart above provides a comprehensive visual representation of Coherus BioSciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Coherus BioSciences shares. Our platform offers an up-to-date CHRS stock price chart, along with technical data analysis and alternative data insights.
Does CHRS offer dividends to its shareholders?
As of our latest update, Coherus BioSciences (CHRS) does not offer dividends to its shareholders. Investors interested in Coherus BioSciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Coherus BioSciences?
Some of the similar stocks of Coherus BioSciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.